Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways

INTRODUCTION: Cardiac dysfunction is among the serious side effects of therapy with recombinant humanized anti-erbB2 monoclonal antibody. The antibody blocks ErbB-2, a receptor tyrosine kinase and co-receptor for other members of the ErbB and epidermal growth factor families, which is over-expressed...

Descripción completa

Detalles Bibliográficos
Autores principales: Pugatsch, Thea, Abedat, Suzan, Lotan, Chaim, Beeri, Ronen
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779483/
https://www.ncbi.nlm.nih.gov/pubmed/16839426
http://dx.doi.org/10.1186/bcr1523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779483/
https://www.ncbi.nlm.nih.gov/pubmed/16839426
http://dx.doi.org/10.1186/bcr1523

Ejemplares similares